Background/Aim: Sorafenib is now standard treatment for advanced hepatocellular
carcinoma (HCC). However, therapeutic efficacy is not as good as was predicted. Many …

Background Post‐operative liver regeneration may contribute to tumor recurrence. There is
a theoretical need for an adjuvant therapy that can suppress tumor growth without adversely …

Abstract Background: The anti-angiogenic Sorafenib is the only approved systemic therapy
for advanced hepatocellular carcinoma (HCC). However, acquired resistance limits its …

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality
worldwide. The AKT pathway is often activated in HCC cases, and a longer exposure to …

Background The combination of bevacizumab (B) and erlotinib (E) has shown promising
clinical outcomes as the first-line treatment of advanced HCC patients. We aimed to evaluate …

The approval of sorafenib as the first effective drug for the treatment of hepatocellular
carcinoma (HCC) represents a milestone in the treatment of this disease. A better …

Resistance is one limitation of sorafenib in the treatment of hepatocellular carcinoma (HCC).
Insulin-like growth factor-1 receptor (IGF-1R) is involved in cancer cell proliferation. To …

The limited availability of experimental tumor models that faithfully mimic the progression of
human tumors and their response to therapy remains a major bottleneck to the clinical …

Purpose Severe adverse events frequently occur in patients treated with sorafenib, whereas
some patients have suboptimal response to sorafenib. We aimed to evaluate the association …

Abstract Lessons Learned The combination of trametinib and sorafenib has an acceptable
safety profile, albeit at doses lower than approved for monotherapy. Maximum tolerated …